Zasocitinib is an investigational, once-daily, highly selective oral tyrosine kinase 2 inhibitor being developed for immune-mediated inflammatory diseases.
Retatrutide beneficial as a monotherapy in adults with T2D inadequately controlled with diet and exercise alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results